Abstract: A method of making HIV protease inhibitors of general formula (1): These HIV compounds inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optically other antiviral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

Abstract: A method of making HIV protease inhibitors of general formula (1): 1

Abstract: Compounds useful as intermediates in the preparation of HIV protease inhibitors.

Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optically other antiviral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

Abstract: This invention provides compounds of the Formula I: which are useful as tachykinin receptor antagonists. This invention also provides methods employing these compounds, as well as pharmaceutical formulations comprising these compounds.

Abstract: This invention provides a series of substituted propanamines useful as tachykinin receptor antagonists. This invention also provides methods employing these substituted propanamines as well as pharmaceutical formulations comprising these compounds.

Abstract: A shock-resistant electronic circuit assembly (10) is provided in which an electronic circuit is encased in an encapsulation (14) that engages a surrounding enclosure (18) in shock-dispersing contact therewith. The encapsulation may have a plurality of edges (16, 16a, 16b), fins (24) or bosses (70) that bear against the enclosure. The encapsulation may include a shock-absorbing material (14f) disposed against the enclosure to protect the circuit against vibrations and a structural support material such as a casing (14e) to protect the circuit against stress. The circuit assembly (10) may be part of a sheathed initiator assembly (55) that includes a transfer member (58) for converting shock wave energy into electrical energy for the electronic circuit, and the released energy may be converted into a detonation initiation signal. Assembly (55) may be part of a detonator (100) that receives a non-electric initiation signal and detonates following the delay determined by the electronic circuit.

Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optically other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

Abstract: This invention provides novel 5-HT.sub.1F agonists of Formula ##STR1## where X, R.sup.1, R.sup.2, and R.sup.3 are defined in the specification, which are useful for the treatment of migraine and associated disorders.

Abstract: A flat-form separation device (12) is made of two half-section members (22, 22') which are fastened together by a series of fasteners (38) to define therebetween a receiving channel within which an expansion device (40) is received. Aside from the receiving channel and any apertures which are to receive mechanical fasteners, the separation device (12) is solid throughout and free of other channels or cavities. The device (12) includes a pair of joinder flanges formed by mating half-flange segments (28a and 28b), which contain apertures (32 and 34) by which the flat-form separation device (12) may be secured to structures (48, 50) which are to be temporarily joined by the device (12). Because of the cross-sectional profile of the half-section members (22, 22'), they may be made by manufacturing techniques, such as machining, which enable the use of alloys or metals which are much tougher and stronger than those which can be extraded to form prior art hollow-form separation devices (14).

Abstract: A shock-resistant electronic circuit assembly (10) is provided in which an electronic circuit is encased in an encapsulation (14) that engages a surrounding enclosure (18, 22) in shock-dispersing contact therewith. The encapsulation may have a plurality of edges (16, 16a, 16b), fins (24) or bosses (70) that bear against the enclosure. The encapsulation may include a shock-absorbing material (14f) disposed against the enclosure to protect the circuit against vibrations and a structural support material (14e) to protect the circuit against stress. The circuit assembly (10) may contain a capacitor (34) for storing an electrical signal and timing circuitry for releasing the stored energy after a predetermined delay. The circuit assembly (10) may be part of a transducer-circuit assembly (55) that includes a transducer module (58) for converting shock wave energy into electrical energy for the electronic circuit, and the released energy may be converted into a detonation initiation signal.

Abstract: The present invention provides compounds which inhibit an envelope virus by inhibiting the fusion of the virus with the host cell. The virus may be inhibited in an infected cell, a cell susceptible of infection or a mammal in need thereof.

Abstract: A manifold (130) is configured to have a body portion (131) having at least one initiation port (132) for receiving an initiation device and at least one tapered boss (138) mounted on the body portion (131). The boss (138) has an elliptical cross-sectional configuration and a boss bore (140) for receiving a fuse or linear explosive charge (16) and it communicates with the initiation port (132). There is a clamp member (160) having an aperture (164) dimensioned and configured to generally conform to the boss (138), and tension means such as a set of bolts (166) for urging the clamp member (160) towards the manifold (130). There may be a bushing material (121) on the boss. The manifold (130) may be coupled to a separation device (23) that includes a frangible joint (24) through which is disposed an expansion member (110).

Abstract: The present invention relates to compounds used for increasing activation of the 5-HT1F receptor.

Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

Abstract: The invention provides novel 5-HT.sub.1f agonists of formula (I) where X, R.sup.1, R.sup.2, and R.sup.3 are defined in the specification, which are useful for the treatment of migraine and associate disorders.

Abstract: A sealing device (30) is provided for sealing the interior of a pressure vessel such as the containment tube (20) of a separation device (8). The sealing device may comprises a detonation manifold (130, 230 or 330) having a body portion (31) having at least one initiation port (32) for receiving a secondary device such as initiation devices (15a, 15b) and at least one mounting boss (138 or 238) having an annular locking channel (162 or 262) along the side surface (138b or 238b) of the mounting boss. A locking collar (150 or 250) having an integral crimping band (158 or 258) which extends along and protrudes from an inner circumferential contact surface (151 or 251) of locking collar (150 or 250).

Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.